An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status.

"Conflicts of interest statement Arie E. van der Bijl has no conflicts of interest pertaining to this article. Ferdinand Breedveld has received consulting fees or honoraria (less than $10,000 per year) from Centocor, Schering-Plough, Amgen/Wyeth, and Abbott. Christian Antoni received research grants, consulting fees, and other remuneration from Centocor, Schering-Plough, and Abbott Laboratories. Employee of Scherring-Plough. Joachim Kalden is active as a consultant for Abbott, MSD, Roche, Wyeth, Centocor, and Schering-Plough. Sonja Kary is an employee and holds stock/stock options for Abbott Laboratories; Consulting fees - Bristol Meyer Squibb. Gerd Burmester has received honoraria and consulting fees from Abbott and is on the Abbott speakers bureau. Christina Beckmann is employed by Abbott Laboratories. Kristina Unnebrink is employed by Abbott Laboratories and holds Abbott stock options. Hartmut Kupper is employed by Abbott Laboratories and holds Abbott stock options."

"The authors thank the physicians and staff members of all study centers for having participated in this study. In addition, we thank Susan Paulson, PhD, for the performance of pharmacokinetic analyses, and Angela Cimmino, PharmD, who provided writing assistance on behalf of Abbott Laboratories. The study was sponsored by Abbott Laboratories."